Compare NVAX & PWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVAX | PWP |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1995 | N/A |
| Metric | NVAX | PWP |
|---|---|---|
| Price | $8.30 | $21.10 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 3 |
| Target Price | $10.78 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 6.4M | 1.1M |
| Earning Date | 02-26-2026 | 02-06-2026 |
| Dividend Yield | N/A | ★ 1.27% |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.07 | 0.70 |
| Revenue | ★ $1,064,651,000.00 | $757,415,000.00 |
| Revenue This Year | $58.91 | N/A |
| Revenue Next Year | N/A | $41.37 |
| P/E Ratio | ★ $4.20 | $31.81 |
| Revenue Growth | ★ 20.27 | N/A |
| 52 Week Low | $5.01 | $14.12 |
| 52 Week High | $10.65 | $26.94 |
| Indicator | NVAX | PWP |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 54.50 |
| Support Level | $9.16 | $21.46 |
| Resistance Level | $10.20 | $22.88 |
| Average True Range (ATR) | 0.69 | 1.00 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 22.67 | 52.88 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.